The net value of health care for patients with type 2 diabetes, 1997 to 2005

Annals of Internal Medicine

Volumn 151, Issue 6, 2009, Pages 386-393

  Eggleston, Karen N ^b   Shah, Nilay D ^c   Smith, Steven A ^d   Wagie, Amy E ^c   Williams, Arthur R ^e   Grossman, Jerome H ⁱ   Berndt, Ernst R ^f   Long, Kirsten Hall ^g   Banerjee, Ritesh ^h   Newhouse, Joseph P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d Mayo Clinic College of Medicine   (United States)

^e CHILDREN S MERCY HOSPITAL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g Center for Prevention   (United States)

^h ANALYSIS GROUP   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; FEMALE; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; SOCIOECONOMICS; SURVIVAL;

EID: 70349122165     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-151-6-200909150-00003     Document Type: Article

References (36)

1. Cutler DM, McClellan M, Newhouse JP, Remler D. Are medical prices declining? Evidence from health attack treatments. Q J Econ. 1998;113:991-1024. (Pubitemid 128161439)
2. Berndt ER, Bir A, Busch SH, Frank RG, Normand SL. The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes. J Health Econ. 2002;21:373-396 [PMID: 12022264]
3. Shapiro I, Shapiro M, Wilcox D. A price index for cataract surgery. In: Cutler D, Berndt E, eds. Medical Output and Productivity. Chicago: Univ Chicago Pr; 2001:411-438
4. Berndt ER, Cutler C, Frank RG, Griliches Z, Newhouse JP, Triplett JE. Medical care prices and output. In: Newhouse JP, Culyer AC, eds. Handbook of Health Economics. vol.1A. Amsterdam: Elsevier Science; 2000:119-180
5. Scitovsky AA. Changes in the costs of treatment of selected illnesses, 1951-1965. Am Econ Rev. 1967;57:1182-1195
6. Scitovsky AA. Changes in the costs of treatment of selected illnesses, 1971-1981. Med Care. 1985;23:1345-1357 [PMID: 4087950]
7. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787 [PMID: 11742409] (Pubitemid 34000780)
8. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932 [PMID: 12610059]
9. Nathan DM. Finding new treatments for diabetes - how many, how fast . . . how good? N Engl J Med. 2007;356:437-440 [PMID: 17267901]
10. Rubin RJ, Dietrich KA, Hawk AD. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. J Clin Endocrinol Metab. 1998;83:2635-2642 [PMID: 9709924]
11. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124 [PMID: 10388977]
12. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285:182-189 [PMID: 11176811] (Pubitemid 32048520)
13. Fireman B, Bartlett J, Selby J. Can disease management reduce health care costs by improving quality? Health Aff (Millwood). 2004;23:63-75.
14. Kupersmith J, Francis J, Kerr E, Krein S, Pogach L, Kolodner RM, et al. Advancing evidence-based care for Diabetes: Lessons from the Veterans Health Administration. Health Aff (Millwood). 2007;26:w156-68.
15. Beaulieu N, Cutler DM, Ho K, Isham G, Lindquist T, Nelson A, O'Connor P. The Business Case for Diabetes Disease Management for Managed Care Organizations. Forum for Health Economics & Policy. 2006;9:1. Accessed at www.bepress.com/fhep/9/1/1 on 21 July 2009.
16. Gorman CA, Zimmerman BR, Smith SA, Dinneen SF, Knudsen JB, Holm D, et al. DEMS - a second generation diabetes electronic management system. Comput Methods Programs Biomed. 2000;62:127-140 [PMID: 10764939] (Pubitemid 30182599)
17. Montori VM, Dinneen SF, Gorman CA, Zimmerman BR, Rizza RA, Bjornsen SS, et al; Translation Project Investigator Group. The impact of planned care and a diabetes electronic management system on community-based diabetes care: the Mayo Health System Diabetes Translation Project. Diabetes Care. 2002;25:1952-1957 [PMID: 12401738]
18. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671-679 [PMID: 11724655]
19. Lee JD, Morrissey JR, Patel V; Alphabet POEM Project (Practice of Evidence-Based Medicine). Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). Curr Med Res Opin. 2004;20:765-772 [PMID: 15140344]
20. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med. 2004;21:238-245 [PMID: 15008833]
21. Hahn RA. The state of federal health statistics on racial and ethnic groups. JAMA. 1992;267:268-271 [PMID: 1727525]
22. Melton LJ 3rd. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266-274 [PMID: 8594285]
23. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al; UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747-1759 [PMID: 15517152]
24. Viscusi WK, Aldy JE. The value of a statistical life: A critical review of market estimates throughout the world. J Risk Uncertain. 2003;27:5-76. (Pubitemid 37089832)
25. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349-356 [PMID: 18362813]
26. Rosen AB, Cutler DM, Norton DM, Hu HM, Vijan S. The value of coronary heart disease care for the elderly: 1987-2002. Health Aff (Millwood). 2007;26:111-123
27. Gold ML, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine: The Report of the Panel on Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
28. Huang ES, Zhang Q, Brown SE, Drum ML, Meltzer DO, Chin MH. The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers. Health Serv Res. 2007;42:2174-93; discussion 2294-2323 [PMID: 17995559] (Pubitemid 350077336)
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853 [PMID: 9742976]
30. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572 [PMID: 18539916]
31. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559 [PMID: 18539917]
32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589 [PMID: 18784090]
33. Montori VM, Fernández-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med. 2009;150:803-808 [PMID: 19380837]
34. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168:2088-2094 [PMID: 18955637]
35. Christensen CM, Grossman JH, Hwang J. The Innovator's Prescription: A Disruptive Solution for Health Care. New York: McGraw Hill; 2009.
36. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461-494 [PMID: 11469231]